| Project/Area Number |
20780099
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Food science
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
TSUDUKI Tsuyoshi Tohoku University, 大学院・農学研究科, 准教授 (00404848)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 共役脂肪酸 / 血管新生 / リノレン酸 / エレオステアリン酸 / 共役リノレン酸 / 共役リノール酸 / キリ / ニガウリ |
|---|
| Research Abstract |
In the current study, the antiangiogenic effects of ESA were investigated in vitro. ESA also inhibited the formation of capillary-like networks by human umbilical vein endothelial cells (HUVEC) and moderately inhibited HUVEC proliferation and migration in a dose-dependent manner. The mechanism by which ESA inhibited angiogenesis was through activation of peroxisome proliferator-activated receptor (PPAR) γ and induction of apoptosis in HUVEC. We thus demonstrated that, like troglitazone, ESA is a PPARγ ligand, and that it activates PPARγ, induces apoptosis in HUVEC, and inhibits angiogenesis. Our findings suggest that ESA has potential use as a therapeutic dietary supplement and medicine for minimizing tumor angiogenesis.
|
